| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FMK | GDSC1000 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | VX-680 | GDSC1000 | pan-cancer | AAC | -0.042 | 0.4 |
| mRNA | PDMP | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | -0.089 | 0.4 |
| mRNA | Epothilone B | GDSC1000 | pan-cancer | AAC | 0.027 | 0.4 |
| mRNA | PHA-793887 | GDSC1000 | pan-cancer | AAC | 0.022 | 0.4 |
| mRNA | selumetinib:BRD-A02303741 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |